Patient Characteristics
| Patient | Group | Age (y) | Sex | Primary tumor | Primary site | Secondary site | Previous treatment | Ongoing treatment | Interval between diagnosis and RT (y) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | A | 63 | F | Carcinoid | Midgut | L, N, C | Sur, Chem | — | 13 |
| 2 | A | 53 | M | NET | Unknown | L, N, C | Sur, Chem | — | 3 |
| 3 | A | 57 | M | Carcinoid | Pancreas | L | Sur, Chem | Oct 400 mg | 10 |
| 4 | A | 52 | F | Carcinoid | Unknown | N | Sur, Chem | Oct 400 mg | 8 |
| 5 | A | 56 | M | Carcinoid | Midgut | L, N | Chem | Oct 600 mg | 1.5 |
| 6 | A | 59 | M | Carcinoid | Midgut | L, N, C | Sur, Chem | Lan 30 mg | 0.75 |
| 7 | A | 64 | M | NET | Pancreas | L | Sur, Chem | — | 3 |
| 8 | A | 64 | F | NET | Unknown | L, N, C | Chem | — | 8 |
| 9 | A | 71 | M | Vipoma | Pancreas | L, B | Chem, Rad | Oct 600 mg, analgesic | 7 |
| 10 | A | 66 | F | Carcinoid | Midgut | L, B | Chem | Oct 400 mg | 4 |
| 11 | A | 80 | M | Carcinoid | Unknown | L, N | Sur, Chem | Oct 1,000 mg, parenteral nutrition | 15 |
| 12 | A | 57 | M | NET | Pancreas | L, B | Chem | — | 1.5 |
| 13 | A | 68 | F | Carcinoid | Midgut | L, N, C | Sur, Chem | Oct 1,500 mg | 26 |
| 14 | A | 62 | F | Carcinoid | Midgut | L | Sur, Chem | Lan 30 mg | 15.75 |
| 15 | A | 49 | M | NET | Hindgut | L, B, C | Sur, Chem | — | 8.25 |
| 16 | A | 68 | M | Gastrinoma | Unknown | L | Sur, Chem | Oct 300 mg | 3 |
| 17 | A | 61 | F | Carcinoid | Midgut | L, N, B | Chem | Oct 400 mg | 5 |
| 18 | A | 53 | M | Carcinoid | Midgut | L, N | Chem | — | 1.8 |
| 19 | A | 70 | F | NET | Midgut | L | Chem | Oct 1,500 mg | 15 |
| 20* | A | 37 | M | Vipoma | Pancreas | L, P | Chem | Analgesic | 6 |
| Mean ± SD | 61.8 ± 7.8 | 12 M/ 8 F | — | — | — | 7.9 ± 6.6 | |||
| 21 | B | 62 | M | Gastrinoma | Pancreas | L, B | Chem | — | 0.5 |
| 22 | B | 74 | F | Carcinoid | Midgut | L, C | Chem | — | 0.7 |
| 23 | B | 40 | F | Gastrinoma | Pancreas | L | Chem | Oct 400 mg | 0.7 |
| 24 | B | 58 | M | Gastrinoma | Pancreas | L | Sur, Chem | — | 16.6 |
| 25 | B | 79 | M | NET | Pancreas | L, N, A | Sur, Chem | — | 1.7 |
| 26 | B | 50 | F | Gastrinoma | Pancreas | L, N, C | Chem, ChEmb | Oct 200 mg | 18 |
| 27 | B | 71 | M | Glucagonoma | Pancreas | L, N | Sur, Chem | Oct 400 mg | 5 |
| 28 | B | 59 | M | Gastrinoma | Pancreas | N, C, A | Sur, Chem | Oct 600 mg | 18 |
| 29 | B | 67 | F | Carcinoid | Midgut | L | Sur, Chem | Oct 750 mg | 15 |
| 30 | B | 65 | F | Gastrinoma | Pancreas | L | Sur, Chem | — | 18 |
| 31 | B | 81 | F | Carcinoid | Midgut | N, B, C | — | Lan 30 mg | 5 |
| 32 | B | 85 | F | Insulinoma | Pancreas | L, N | Chem | Oct 400 mg | 21.75 |
| Mean ± SD | — | 65.9 ± 13.2 | 5 M/ 7 F | — | — | — | — | — | 10.0 ± 8.4 |
| P between groups | NS | NS | NS |
RT = radionuclide therapy; NET = neuroendocrine tumor; L = liver; N = lymph nodes; C = chest; Sur = surgery; Chem = chemotherapy; Oct = Octreotide; Lan = Lanreotide; B = bone; Rad = radiotherapy; P = peritoneum; A = adrenal; ChEmb = chemoembolization; NS = nonsignificant.
↵* Patient excluded from quantitative analysis during follow-up.